A Phase IIa Trial With Dose Optimization of OTX015, a Small Molecule Inhibitor of the Bromodomain and Extra-terminal (BET) Proteins, in Recurrent Glioblastoma Multiforme (GBM) Patients

Trial Profile

A Phase IIa Trial With Dose Optimization of OTX015, a Small Molecule Inhibitor of the Bromodomain and Extra-terminal (BET) Proteins, in Recurrent Glioblastoma Multiforme (GBM) Patients

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 07 Jun 2016

At a glance

  • Drugs Birabresib (Primary)
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Sponsors OncoEthix
  • Most Recent Events

    • 07 Jun 2016 Results (n=12) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 17 Dec 2015 Status changed from active, no longer recruiting to discontinued, as reported by ClinicalTrials.gov.
    • 04 Sep 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top